Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Tetra-Pharm-Tech-CB1

More Like This

PR Newswire associated0

Tetra Pharm Technologies introduces pain relieving drug in the United Kingdom

PR Newswire associated0

Tetra Pharm Technologies and Kvantify Announce Partnership to Accelerate the Discovery of Novel Drug Candidates Targeting the Endocannabinoid System

PR Newswire associated0

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

PR Newswire associated0

Tetra Pharm Technologies Relocates to Copenhagen Towers

TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation

PR Newswire associated0

Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development